Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Outcomes of neovascular glaucoma secondary to proliferative diabetic retinopathy treated with surgical therapies in real-world clinical setting
Author Affiliations & Notes
  • Kenji Miyao
    Ophthalmology, National Defense Medical College, Tokorozawa, Saitama, Japan
  • Takayuki Kanda
    Ophthalmology, National Defense Medical College, Tokorozawa, Saitama, Japan
  • Kozo Harimoto
    Ophthalmology, National Defense Medical College, Tokorozawa, Saitama, Japan
  • Rina Okazawa
    Ophthalmology, National Defense Medical College, Tokorozawa, Saitama, Japan
  • Riki Kitamura
    Ophthalmology, National Defense Medical College, Tokorozawa, Saitama, Japan
  • Tomohito Sato
    Ophthalmology, National Defense Medical College, Tokorozawa, Saitama, Japan
  • Masaru Takeuchi
    Ophthalmology, National Defense Medical College, Tokorozawa, Saitama, Japan
  • Footnotes
    Commercial Relationships   Kenji Miyao None; Takayuki Kanda None; Kozo Harimoto None; Rina Okazawa None; Riki Kitamura None; Tomohito Sato None; Masaru Takeuchi None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 1771. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kenji Miyao, Takayuki Kanda, Kozo Harimoto, Rina Okazawa, Riki Kitamura, Tomohito Sato, Masaru Takeuchi; Outcomes of neovascular glaucoma secondary to proliferative diabetic retinopathy treated with surgical therapies in real-world clinical setting. Invest. Ophthalmol. Vis. Sci. 2024;65(7):1771.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Neovascular glaucoma (NVG), a severe complication of proliferative diabetic retinopathy (PDR), can lead to irreversible vision loss. Surgical intervention is often necessary to control intraocular pressure (IOP) and preserve visual acuity (VA) in NVG patients. In this study, we investigated VA and IOP in PDR-associated NVG patients treated with surgical therapies in a clinical setting.

Methods : A retrospective analysis of medical records was conducted for 35 consecutive PDR-associated NVG patients who underwent surgical treatments in our institution between 2013 and 2022. Patient demographics, clinical characteristics, surgical procedures of pars plana vitrectomy with extensive panretinal and ciliary photocoagulation (PPV-PRCP), diode laser trans-scleral cyclophotocoagulation (DCPC), and trabeculectomy with mitomycin C (TLE-MMC) with or without prior intravitreal bevacizumab injection (IVB), and VA and IOP at the first and last visits were reviewed.

Results : The mean patient age was 62.9 ± 12.1 years, with a male-to-female ratio of 26:9. The mean follow-up period was 34.0±34.5 months. Two patients (5.7%) each underwent PPV-PRCP or DCPC alone, 3 patients (8.6%) had TLE-MMC alone, 2 patients (5.7%) had TLE-MMC after IVB, 7 patients (20.0%) had PPV-PRCP and TLE-MMC, 8 patients (22.9%) had PPV-PRCP and TLE-MMC after IVB, 5 patients (14.3%) had PPV-PRCP and DCPC and TLE-MMC, and 4 patients (11.4%) had PPV-PRCP and DCPC and TLE-MMC after IVB. Mean logMAR VA was 1.25 ± 1.0 at the first visit and 1.25 ± 1.08 at the last visit, with no significant change. However, the number of patients with no light perception increased from 3 to 6. Mean IOP was 31.9 ± 14.8 mmHg at the initial visit and decreased significantly to 13.9 ± 7.0 mmHg at the last visit (< 0.0001). Number of eyes with IOP ≧ 21 decreased from 30 (85.7%) to 3 (8.6%). Hypotony (≦ 5 mmHg) was observed in 4 eyes (11.4%).

Conclusions : Various surgical techniques can effectively manage NVG associated with PDR. The surgical procedure should be individualized based on the patient's clinical characteristics and disease severity. A combination of surgical approaches may be necessary to achieve optimal IOP control and preserve vision.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×